Literature DB >> 8950679

Loss of heterozygosity in tuberous sclerosis hamartomas.

T Sepp1, J R Yates, A J Green.   

Abstract

We have previously described in tuberous sclerosis (TSC) hamartomas the phenomenon of loss of heterozygosity (LOH) for DNA markers in the region of both the TSC2 gene on chromosome 16p13.3 and the TSC1 gene on 9q34. We now describe the spectrum of LOH in 51 TSC hamartomas from 34 cases of TSC. DNA was extracted from leucocytes or normal paraffin embedded tissue, and from frozen paraffin embedded hamartoma tissue from the same patient. The samples were analysed for 11 markers spanning the TSC1 locus and nine markers spanning the TSC2 locus. Twenty-one of 51 hamartomas showed LOH (41%). There was significantly more LOH on 16p13.3, with 16 hamartomas showing LOH around TSC2, and five in the vicinity of TSC1. No hamartoma showed LOH for markers around both loci. All the areas of LOH on chromosome 9 were large, but the smallest region of overlap lay between the markers D9S149 and D9S114, providing independent evidence for the localisation of the TSC1 gene. These data show that LOH is a common finding in a wide range of hamartomas, affecting the same TSC locus in different lesions from the same patient but not affecting both loci. These data support the hypothesis that both the TSC genes act as tumour suppressors and that the manifestations of TSC in patients with germline TSC mutations rise from "second hit" somatic mutations inactivating the remaining normal copy of the TSC gene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8950679      PMCID: PMC1050793          DOI: 10.1136/jmg.33.11.962

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  8 in total

1.  Report and abstracts of the Third International Workshop on Chromosome 9. Cambridge, United Kingdom, 9-11 April, 1994.

Authors:  S Povey; J Armour; P Farndon; J L Haines; M Knowles; F Olopade; A Pilz; J A White; D J Kwiatkowski
Journal:  Ann Hum Genet       Date:  1994-07       Impact factor: 1.670

2.  Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas.

Authors:  E P Henske; H P Neumann; B W Scheithauer; E W Herbst; M P Short; D J Kwiatkowski
Journal:  Genes Chromosomes Cancer       Date:  1995-08       Impact factor: 5.006

3.  Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients.

Authors:  A J Green; M Smith; J R Yates
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

4.  Two loci for tuberous sclerosis: one on 9q34 and one on 16p13.

Authors:  S Povey; M W Burley; J Attwood; F Benham; D Hunt; S J Jeremiah; D Franklin; G Gillett; S Malas; E B Robson
Journal:  Ann Hum Genet       Date:  1994-05       Impact factor: 1.670

5.  The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor.

Authors:  A J Green; P H Johnson; J R Yates
Journal:  Hum Mol Genet       Date:  1994-10       Impact factor: 6.150

6.  Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity.

Authors:  R Wienecke; A König; J E DeClue
Journal:  J Biol Chem       Date:  1995-07-07       Impact factor: 5.157

7.  Apparent preferential loss of heterozygosity at TSC2 over TSC1 chromosomal region in tuberous sclerosis hamartomas.

Authors:  C Carbonara; L Longa; E Grosso; G Mazzucco; C Borrone; M L Garrè; M Brisigotti; G Filippi; A Scabar; A Giannotti; P Falzoni; G Monga; G Garini; M Gabrielli; P Riegler; C Danesino; M Ruggieri; G Magro; N Migone
Journal:  Genes Chromosomes Cancer       Date:  1996-01       Impact factor: 5.006

8.  9q34 loss of heterozygosity in a tuberous sclerosis astrocytoma suggests a growth suppressor-like activity also for the TSC1 gene.

Authors:  C Carbonara; L Longa; E Grosso; C Borrone; M G Garrè; M Brisigotti; N Migone
Journal:  Hum Mol Genet       Date:  1994-10       Impact factor: 6.150

  8 in total
  37 in total

1.  Complete inactivation of the TSC2 gene leads to formation of hamartomas.

Authors:  K S Au; A A Hebert; E S Roach; H Northrup
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

2.  Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development.

Authors:  G Rennebeck; E V Kleymenova; R Anderson; R S Yeung; K Artzt; C L Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

3.  Mutations in the TSC1 gene account for a minority of patients with tuberous sclerosis.

Authors:  J B Ali; T Sepp; S Ward; A J Green; J R Yates
Journal:  J Med Genet       Date:  1998-12       Impact factor: 6.318

Review 4.  New frontiers in modeling tuberous sclerosis with human stem cell-derived neurons and brain organoids.

Authors:  John D Blair; Helen S Bateup
Journal:  Dev Dyn       Date:  2019-05-23       Impact factor: 3.780

5.  Neural progenitors derived from Tuberous Sclerosis Complex patients exhibit attenuated PI3K/AKT signaling and delayed neuronal differentiation.

Authors:  Avery J Zucco; Valentina Dal Pozzo; Alina Afinogenova; Ronald P Hart; Orrin Devinsky; Gabriella D'Arcangelo
Journal:  Mol Cell Neurosci       Date:  2018-08-23       Impact factor: 4.314

Review 6.  Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

Authors:  Jeffrey P MacKeigan; Darcy A Krueger
Journal:  Neuro Oncol       Date:  2015-08-19       Impact factor: 12.300

7.  Analysis of loss of heterozygosity in Korean patients with keratoacanthoma.

Authors:  Tae-Won Ha; Ki-Hwan Han; Dae-Gu Son; Sang-Pyo Kim; Dae-Kwang Kim
Journal:  J Korean Med Sci       Date:  2005-04       Impact factor: 2.153

Review 8.  A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits.

Authors:  David M Feliciano; Tiffany V Lin; Nathaniel W Hartman; Christopher M Bartley; Cathryn Kubera; Lawrence Hsieh; Carlos Lafourcade; Rachel A O'Keefe; Angelique Bordey
Journal:  Int J Dev Neurosci       Date:  2013-02-26       Impact factor: 2.457

Review 9.  Subependymal giant cell astrocytoma: current concepts, management, and future directions.

Authors:  Taohui Ouyang; Na Zhang; Thomas Benjamin; Long Wang; Jiantong Jiao; Yiqing Zhao; Jian Chen
Journal:  Childs Nerv Syst       Date:  2014-02-19       Impact factor: 1.475

10.  Tsc1 haploinsufficiency is sufficient to increase dendritic patterning and Filamin A levels.

Authors:  Longbo Zhang; Tianxiang Huang; Angélique Bordey
Journal:  Neurosci Lett       Date:  2016-06-21       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.